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Abstract
Objective. To define predictors for the 2-year outcome in terms of achieving inactivity, subsequent uveitis reactivation
and occurrence of uveitis-related complications of JIA-associated uveitis.
Methods. Demographic and clinical parameters and serum samples of JIA-associated uveitis patients enrolled in ICON
at 41 year of JIA diagnosis were collected at study enrolment, every 3 months during the first year and subsequently
every 6 months. Predictors for the 2-year outcome were evaluated by linear mixed models.
Results. Of 954 JIA patients included, uveitis occurred in 106 up to the first 2-year follow-up, with 98 of them having
complete ophthalmological documentation. In 81.8% and 80.0% of patients, uveitis inactivity was achieved at the 1- and
2-year follow-up after uveitis onset, respectively. JIA onset after the age of 5 years, no use of topical corticosteroids, and
adalimumab treatment were significantly associated with an inactive uveitis for at least 6 months (n= 57). Correlates for
subsequent uveitis reactivation (n= 16, 30.2%) were age at uveitis onset 45 years and active disease (clinical Juvenile
Arthritis Disease Activity Score >4.5). Uveitis-related complications were present in 29.8% of patients at first uveitis
documentation and in 30.7% and 32.8% at 1- and 2-year follow-up, respectively. Older age at JIA onset, short duration
between JIA and uveitis onset, high anterior chamber (AC) cell grades, poor visual acuity, and topical steroid use at first
uveitis documentation correlated with uveitis-related complications.
Conclusion. In addition to demographic risk factors, JIA disease and uveitis activity scores and adalimumab are
significant predictors for the 2-year outcome of JIA-associated uveitis patients.
Key words: adalimumab, DMARDs, juvenile idiopathic arthritis, predictors, uveitis
Rheumatology key messages
. In this prospective study, predictors for the 2-year outcome of uveitis were defined in JIA patients.
. Demographic risk factors, JIA and uveitis activity scores and adalimumab determined the 2-year uveitis outcome.
Introduction
Uveitis is a significant cause of visual morbidity in children
with JIA, which is one of the diseases most frequently
associated with the condition [1]. According to the
International League of Associations for Rheumatology
criteria, JIA comprises a heterogeneous group of arthritis
of yet unknown cause and with onset before 16 years of
age, characterized by joint inflammation lasting56 weeks
[2]. As vision-threatening complications develop in more1Department of Ophthalmology at St Franziskus Hospital, University of
Duisburg-Essen, Mu¨nster, 2German Rheumatism Research Center, a
Leibniz Institute, Berlin, 3Institute for Social Medicine, Epidemiology
and Health Economics, Charite´  University Medicine Berlin, Berlin,
Germany, 4Department of Ophthalmology, Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland, 5Ophthalmology, Bonn,
6Department of Paediatric Rheumatology and Immunology, University
of Muenster, Mu¨nster and 7Department of Rheumatology and Clinical
Immunology Charite´  University Medicine Berlin, Berlin, Germany
Correspondence to: Arnd Heiligenhaus, Department of Ophthalmology
at St Franziskus Hospital, Hohenzollernring 74, 48145 Mu¨nster,
Germany. E-mail: arnd.heiligenhaus@uveitis-zentrum.de
Submitted 23 April 2018; revised version accepted 1 November 2018
! The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
RHEUMATOLOGY
C
L
IN
IC
A
L
S
C
IE
N
C
E
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/advance-article-abstract/doi/10.1093/rheum
atology/key406/5262280 by U
niversitaetsbibliothek Bern user on 01 February 2019
than half of the JIA-associated uveitis (JIAU) children,
there is a high incidence of visual loss, and eye surgery
is frequently required [35]. Currently, treatment of JIAU
comprises topical and systemic corticosteroids, and con-
ventional synthetic and/or biologic DMARDs for achieving
inactivity in refractory disease [6, 7].
New developments in genetics and immunology and
the analysis of environmental factors are instrumental for
better defining, classifying and treating patients with JIA
[8]. Indeed, genetic and environmental factors may influ-
ence the prevalence of JIA and associated uveitis, as it
varies among different geographic regions [9]. Among the
JIA categories, uveitis occurs in 1013% of patients [3,
10], and even at higher percentages in particular sub-
groups. Known risk factors for uveitis incidence include
young age at arthritis onset, oligoarthritis subtype and
short disease duration [3, 11]. ANA [3, 12], elevated ESR
[13] and carrying certain HLA-DRB1 alleles [14, 15] ap-
peared as risk factors for uveitis occurrence in JIA.
Recently, it was suggested that there is a correlation be-
tween elevated S100A8/9 and A12 serum levels and
intraocular inflammation [16]. Indeed, systemic anti-
inflammatory treatment instituted for arthritis may reduce
the risk of uveitis onset in JIA patients [10, 17], particularly
if given early during the disease course [18].
Biomarkers can be implemented in daily routine to iden-
tify JIA patients at particular risk for uveitis occurrence
and a complicated disease course, e.g. for achieving dis-
ease inactivity or if the disease is subsequently reacti-
vated or complications develop. Based on data from the
prospective Inception Cohort of Newly diagnosed patients
with JIA (ICON-JIA) study, clinical and laboratory pre-
dictors for the 2-year outcome of JIA-associated uveitis
were defined in a large cohort of JIA patients.
Methods
Inception cohort of newly diagnosed patients with JIA
(ICON)
ICON is an ongoing, multicentre, observational cohort
study of patients in whom JIA was diagnosed within
12 months before enrolment and who are to be observed
for at least 10 years [19]. JIA was defined according to the
International League of Associations for Rheumatology
criteria [2]. International League of Associations for
Rheumatology diagnoses of all patients were subjected
to a review process to validate the JIA category [19].
The study protocol was approved by the ethics com-
mittee of the Charite´Universita¨tsmedizin Berlin. All par-
ents and patients (of 8 years and above) gave their
informed consent at study inclusion according to the
Declaration of Helsinki. The study reflects the currently
applied standard of care in Germany.
Consecutive JIA patients from 11 paediatric rheumatol-
ogy clinics in Germany were included, reaching 1/3 of
the expected incident JIA cases nationwide during the
recruitment period. Demographic and anamnestic clinical
data, as well as family history and patient-reported out-
comes, were recorded with standardized questionnaires
completed by physicians and parents or patients, re-
spectively. Clinical data, treatment and patient-reported
data were collected at ICON enrolment, quarterly in the
first year of observation and half-yearly thereafter [19],
including rheumatological and ocular assessments.
The paediatric rheumatologists assessed the JIA pa-
tients at each visit. The clinical assessment included the
JIA core set of criteria, such as the active joint count,
physician’s global assessment of disease activity on a nu-
meric rating scale (21-point numeric rating scale [NRS],
010), and whether the disease was clinically inactive ac-
cording to the Wallace criteria [20]. In addition, the clinical
Juvenile Arthritis Disease Activity Score (cJADAS-10) was
calculated. The cJADAS-10 (range 030) includes phys-
ician’s global assessment, parent’s global assessment
and the number of active joints (maximum 10). The
cJADAS-10 thresholds proposed by Consolaro and
Ravelli [21] for oligoarticular and polyarticular JIA were
applied to define disease activity states. The patient or
parent reported about overall well-being on a NRS, func-
tional ability by the Childhood Health Assessment
Questionnaire (CHAQ).
Laboratory parameters recorded at ICON enrolment
included ANA, RF and HLA-B27, whereas ESR, CRP,
and S100A12 [16] were determined at enrolment and
follow-up visits.
A detailed and regular assessment by cooperating
ophthalmologists was performed in all JIAU patients
at each time point, including the clinical characterization
of uveitis, visual acuity, slit-lamp examination, tonometry,
ophthalmoscopy, uveitis-related complications and treat-
ment (ongoing and newly started systemic and topical
treatments). Patients were considered to be off treatment
if they did not receive medication and did not start a new
treatment (e.g. topical corticosteroids) at that visit.
JIAU patients were thoroughly evaluated according to
the Standardization of Uveitis Nomenclature [22] with par-
ticular attention to disease activity (e.g. inactivity = no
anterior chamber (AC) cells in field size 11 mm slit
beam; grade 0), topical and systemic anti-inflammatory
treatment and comprehensive documentation of compli-
cations (e.g. synechiae with number of involved quad-
rants, cataract, macular oedema). Accordingly, anterior
uveitis was defined by the primary site of inflammation
in the anterior chamber, including iritis and iridocyclitis.
Onset of uveitis was described as sudden (typically pain,
eye redness), or insidious (asymptomatic) during the at-
tacks. Intraocular pressure >21 mmHg (ocular hyperten-
sion) and glaucoma (presence of glaucomatous optic disc
damage, or typical visual field loss) were documented.
Best-corrected visual acuity was described as logMAR =
log10 visual acuity fraction.
The first ophthalmologic evaluation in ICON patients
with uveitis was referred to as first uveitis documentation
or uveitis baseline (U-BL), and the subsequent assess-
ment as uveitis follow-up (U-FU). The most recent, regular
ICON visit by the paediatric rheumatologist was desig-
nated for ophthalmological assessment with a maximum
time gap of 4 weeks.
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Outcome
The primary outcome of our study was to determine the
rate of patients with inactive uveitis for 56 months within
2 years after first uveitis documentation, whether under
topical anti-inflammatory medication and systemic
DMARD treatment or not. The secondary outcomes of
the study included subsequent uveitis reactivation and
the presence of uveitis complications. Uveitis reactivation
was analysed in patients who attained inactive uveitis for
at least 6 months. The association of sociodemographic
variables, JIA and uveitis characteristics and treatment
with uveitis inactivity56 months, reactivation and compli-
cations was determined.
Statistical analysis
Descriptive statistics were used to describe the distribu-
tion of categorical and continuously distributed variables.
The primary and secondary outcomes of the study were
analysed by generalized mixed linear models to account
for the longitudinal data structure and the correlation be-
tween assessments within a patient. Furthermore, the
grouping variable eye was introduced in the analyses on
the eye level as an additional cluster variable. These
models result in unbiased effect estimates in the presence
of missing data in the follow-up because a patient is not
excluded from analysis when an assessment is missing.
Clinical and laboratory parameters at baseline (fixed vari-
ables) and treatment (time-varying variables) were as-
sessed in terms of their predictive value for achieving
the primary outcome.
The association of treatment and JIA disease charac-
teristics with the outcomes was analysed on the patient
level. In contrast, uveitis disease characteristics were ana-
lysed on the eye level. If uveitis activity, Tyndall, visual
acuity and topical CS were reported on the patient level,
the data were collapsed for the reporting within a patient
by choosing the eye with worse AC cell score
(Standardization of Uveitis Nomenclature) for the analysis,
and the right eye if the score was similar in both eyes.
A P-value of <0.05 is considered significant. Data ana-
lyses were performed using SAS software (version 9.3;
SAS Institute Inc., Cary, NC, USA).
Results
Demographic factors and patient characteristics
A total of 954 JIA patients were included in this study
(67.2% female, 54.2% ANA positive, mean age at JIA
onset 7.1 (S.D. 4.6) years). Uveitis occurred in a total of
133 patients (13.9%) during the present observation
period of the ICON study (mean follow-up of 45.2 (S.D.
22.1) months). In 106 of the patients, uveitis developed
up to 2 years after enrolment in ICON. In fact, uveitis
occurred before first JIA symptoms in four of the patients
(0.4%), before enrolment in 52 patients (5.5%), in another
26 within the first year (2.7%), and in a further 24 within the
second year (2.5%) after ICON enrolment. For this study,
however, only those 98 (10.3%) patients were included,
for whom the detailed uveitis characterization by the
ophthalmologist was available (Supplementary Fig. 1,
available at Rheumatology online). In these patients,
observed for a mean period of 36 (S.D. 19.1) months, the
uveitis disease course, including uveitis activity and sec-
ondary complications, among other uveitis characteris-
tics, could be investigated. This is a representative
sample of all 133 patients, as the 98 patients did not sig-
nificantly differ with respect to sex (P= 0.168), JIA cat-
egory (P= 0.653), ANA positivity (P= 0.692) and age at
JIA onset (P= 0.358). Of the 98 patients, 76 were female
(77.6%), 83 (84.7%) were ANA positive; the mean age at
uveitis diagnosis was 5.1 (S.D. 3.0) years, and the mean
age at JIA onset was 3.9 (S.D. 3.0) years. JIA categories in
patients with and without uveitis are compared in Table 1.
Uveitis characteristics
The first ophthalmological assessment (U-BL) in patients
with uveitis took place 3.2 (S.D. 5.3) months after uveitis
diagnosis. Anterior uveitis (in 100% of 98 patients) was
bilateral in 39.4% at this time point, in 62.7% at 1-year
and in 68.7% at 2-year U-FU (P < 0.001). Insidious onset
of uveitis was documented in 80.7% (n= 79) of patients at
U-BL, correlating with oligoarthritis in 44 (65.7%) of them.
Onset of uveitis was acute in another four patients (4.8%)
and was unknown in the remaining 14.5%. Mean visual
acuity (logMAR) was 0.21 (S.D. 0.30), 0.08 (S.D. 0.17), and
0.11 (S.D. 0.22) at U-BL, 1-year, and 2-year U-FU
(P= 0.10), and logMAR <0.1 was detected in 84.7% at
U-BL, in 95.5% at 1-year U-FU and in 93.4% of patients
at 2-year U-FU (P= 0.621).
Achievement of uveitis inactivity 56 months with
anti-inflammatory treatment within 2 years after first
uveitis documentation
In 81.8% and 80.0% of the JIAU patients, inactivity of
uveitis was reported at the 1- and 2-year U-FU, respect-
ively. Uveitis inactivity 56 months within the 2-year U-FU
was reported in 57 (58.2%) of 98 JIAU patients, and this
was achieved at a mean of 11.5 (S.D. 15.9) months after
uveitis diagnosis.
57.5% of JIAU patients received methotrexate at U-BL
(for a median of 5.4 months), 73.3% at the 1-year U-FU
and 68.7% at the 2-year U-FU in (P < 0.001). In addition,
adalimumab use increased significantly within the 2 years
after U-BL (6.4%, 14.7%, 22.4% at U-BL, 1-year and 2-
year U-FU, respectively, P < 0.001). At the U-BL, the pa-
tients had been treated with adalimumab for 3.1 months
(median).
Topical and systemic corticosteroids were used at U-
BL in more patients (74.5% and 11.4%, respectively) than
at 1-year (48.0% and 10.3%, respectively) or at 2-year U-
FU (38.8% and 6.3%, respectively) (P < 0.001 for topical
steroids) (see Supplementary Tables 1 and 2, available at
Rheumatology online).
Correlates for uveitis inactivity 56 months’ duration
JIA onset after the age of 4 years and uveitis onset after the
age of 5 years were significantly associated with
56 months inactive uveitis during follow-up. Furthermore,
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adalimumab treatment and no use of topical corticoster-
oids in the involved eyes during the 2-year observation
period were also significantly associated with 56 months
inactive uveitis during follow-up (Table 2). We could not find
a significant association for the numerous other clinical,
laboratory and disease activity parameters at first uveitis
documentation or for other anti-inflammatory medications.
A decreasing JIA disease activity (cJADAS-10: OR 0.76;
95% CI: 0.63, 0.92; P= 0.035; physician’s global: OR 0.92;
95% CI: 0.85, 0.97; P= 0.046) during follow-up was sig-
nificantly associated with sustaining uveitis inactivity.
Correlates for uveitis reactivation
In 16 patients (28% of 57) uveitis was subsequently reac-
tivated after attaining inactive uveitis within 2 years after
U-BL. Fifty-three of the 57 patients with uveitis inactivity
for56 months had sufficient follow-up for analysis of pre-
dictors (Tables 3 and 4). Subsequent uveitis reactivation
(n= 16, 30.2%) was associated with age at uveitis onset
4 5 years. An active disease (cJADAS-10> 4.5) and the
use of topical corticosteroids during U-FU were signifi-
cantly associated with uveitis reactivation.
Uveitis-related complications
Uveitis-related complications were present in 28 patients
(29.8% of 98) at U-BL and in 30.7% and 32.8% at 1-, and
2-year U-FU, respectively. During the follow-up period, a
total of nine patients (12.9% of 70) without complications
at first uveitis documentation developed new uveitis-
related complications (Supplementary Table 3, available
at Rheumatology online indicates changes in eye compli-
cations). Patients with eye complications at the first uveitis
documentation were more likely to show complications at
the 2-year U-FU compared with patients without (73.7%
vs 13.5%, P < 0.001). The number of patients with ocular
hypertension increased during the 2-year follow-up (from
0 at U-BL, to two at 2-year U-FU), possibly related also to
the topical steroid use in these patients (Table 5). The
number of patients with typical inflammation-related eye
complications (e.g. optic disc or macular oedema) was
slightly reduced during the observation period, which is
probably related to the anti-inflammatory treatment.
Meanwhile, the number of other eye complications
increased only insignificantly, and only one patient
required ocular surgery (EDTA chelation for band-kerato-
pathy) during the observation period (Table 5).
Correlates for uveitis complications
Older age at JIA onset, short duration between JIA and
uveitis onset, high AC cell grades 52+, the presence of
complications and poor visual acuity (high logMAR rates)
at first uveitis documentation were significantly associated
with the occurrence of uveitis-related eye complications.
Treatment with topical steroids was positively associated
with the subsequent development of complications
(Table 6).
However, no significant correlation was found between
achievement of uveitis inactivity56 months within 2 years
after first uveitis documentation and occurrence of
uveitis-related eye complications. Nor did the use of con-
ventional synthetic or biologic DMARDs appear to signifi-
cantly alter the rate of eye complications during the follow-
up period. However, combined use of adalimumab and
methotrexate showed a lower rate of eye complications
in follow-up, but without reaching significance (P= 0.09).
Discussion
Achievement of uveitis inactivity and subsequent
reactivation
In this ICON study, patient characteristics and demo-
graphic risk factors compare favourably with previously
published studies [3, 4, 10, 12, 13, 2325]. Our data
show for the first time that patients in whom uveitis in-
activity 56 months was achieved with anti-inflammatory
medication were significantly older at onset of JIA and
uveitis, and the chance to achieve inactivity was particu-
larly high when uveitis had begun after age 5. Herein,
gender did not appear as a predictive factor for response
to DMARD treatment, or subsequent uveitis reactivation,
or development of complications. Previously, male gender
was related to good visual outcome [25]. Others found
that males had an increased risk of developing complica-
tions and worse visual outcome [23, 24, 26, 27], probably
related to the notion that, in boys, uveitis more often mani-
fests earlier in the disease course or is more severe, or
that there is less awareness of disease occurrence in boys
[3, 28]. Others did not find differences in uveitis severity
between males and females [29].
ANA positivity is a well-known predictor for uveitis oc-
currence in JIA patients [3, 11, 12, 18, 30]. In the present
study it was not a significant predictor for the 2-year
outcome of JIAU, which is in agreement with previous
observations [3, 27]. Others found more complications in
ANA-negative than in the ANA-positive patients [31, 32],
probably related to inadequate uveitis screening of JIA
patients.
Elevated ESR appeared as a valid baseline prognostic
factor for uveitis occurrence in JIA patients [13, 27, 29, 33,
34]. According to our present data, it did not appear as a
useful predictor of the further uveitis course, which is
probably influenced by anti-inflammatory treatment insti-
tuted for JIA.
Previous data disclosed that S100 serum levels in JIAU
patients were higher in patients with active uveitis and
suggested that they may reflect eye disease [16]. High
S100A12 levels in JIA patients were significantly asso-
ciated with the risk for uveitis [34]. Our presented data
show that S100A12 might not be a useful biomarker for
monitoring uveitis activity during the course of JIA, prob-
ably influenced by the DMARDs being used to treat the
underlying rheumatic disease [35].
Grading AC cells is an important measure of uveitis ac-
tivity [22], accepted also in JIAU [36] primarily involving
the iris and ciliary body [37, 38]. Herein, baseline AC cell
grade was not a significant predictor for uveitis inactivity
56 months duration. High AC cell scores and the use of
topical corticosteroids at the initial uveitis documentation
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TABLE 4 Association of treatment, change in laboratory markers, and disease activity during follow-up with subsequent
uveitis reactivation
Parameter OR; 95% CI P value
Laboratory marker
ESR 1.02; 0.92, 1.13 0.738
CRP 0.89; 0.67, 1.19 0.433
S100A12 1.01; 0.98, 1.00 0.203
Disease activity
cJADAS-10 >4.5 1.84; 1.18, 7.02 0.017
Physician’s global, NRS 0.80; 0.33, 1.96 0.626
CHAQ 0.04; 0.01, 33.51 0.341
Parent’s global 1.05; 0.57, 1.93 0.878
Pain, NRS 1.15; 0.70, 1.89 0.58
Uveitis activity, AC cell grade/involved eye 2.04; 1.27, 3.26 0.003
Tyndall/involved eye 5.65; 2.09, 15.26 0.001
Visual acuity/involved eye, logMAR 0.60; 0.07, 4.99 0.632
Any uveitis eye complications 1.05; 0.65, 1.48 0.198
Anti-inflammatory treatment
NSAID 1.41; 0.40, 4.95 0.591
Any DMARD —
MTX —
Etanercept ± MTX —
Adalimumab ± MTX 1.03; 0.26, 4.05 0.966
CS, systemic 1.62; 0.27, 9.77 0.596
CS, topical in involved eyes 3.47; 1.36, 8.86 0.01
Subsequent uveitis reactivation (n= 16; 30.2%) until 2 years of follow-up, after achieving uveitis inactivity 56 months. P-value
of less than 0.05 are indicated in bold. AC: anterior cell; CHAQ: Childhood Health Assessment Questionnaire; cJADAS: clinical
juvenile arthritis disease activity score; CS: corticosteroids; NRS: numeric rating scale; OR: odds ratio; PedsQL: Pediatric
Quality of Life Inventory.
TABLE 3 Association of subsequent uveitis reactivation with time-independent clinical parameters
Parameter
Patients without subsequent
uveitis reactivation until
2-year U-FU
Patients with subsequent
uveitis reactivation
until 2-year U-FU OR; 95% CI; P value
37 16
Female, n (%) 26 (70.3%) 12 (75.0%) 0.96; 0.32, 2.91; 0.947
Age at JIA onset, mean (S.D.),
years
4.3 (2.5) 3.2 (1.9) 0.89; 0.71, 1.11; 0.289
Age at uveitis onset, mean (S.D.),
years
4.1 (1.9) 3.8 (1.7) 0.91; 0.82, 0.98; 0.039
Age at uveitis onset >5 years, n (%) 15 (40.5%) 3 (18.8%) 0.67; 0.33, 0.92; 0.034
Interval between JIA and uveitis
onset
0.5 (0.9) 0.6 (0.6) 1.60; 0.70, 3.63; 0.263
JIA category, n (%) —
Polyarthritis RF negative 6 (16.7%) 4 (25.0%)
Oligoarthritis persistent 24 (66.7%) 9 (56.3%)
Oligoarthritis extended 4 (11.1%) 1 (6.3%)
Psoriatic arthritis 0 (0.0%) 1 (6.3%)
Enthesitis-related arthritis 1 (2.8%) 0 (0.0%)
Undifferentiated arthritis 1 (2.8%) 1 (6.3%)
ANA positive, n (%) 32 (86.5%) 12 (75.0%) —
HLA-B27 positive, n (%) 2 (5.4%) 1 (6.3%) 1.70; 0.22; 13.17; 0.608
Association of subsequent uveitis reactivation (n= 16; 28.1%) with time-independent clinical parameters. Fifty-three of 57 patients
with uveitis inactivity for 56 months had sufficient follow-up for analysis. P-value of less than 0.05 are indicated in bold. Due to
colinearity and small numbers, JIA subcategory and ANA could not be estimated. OR: odds ratio; U-FU: uveitis follow-up.
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were associated with subsequent uveitis reactivation.
Accordingly, mild disease was an important predisposing
factor for subsequent remission in a previous study [26],
and a severe disease and worse visual outcome were
previously observed in patients with severe disease at
onset [23, 24, 26].
In previous studies, high Tyndall effect reflected a more
severe uveitis course in terms of uveitis activity and tissue
damage [39]. It is, therefore, conceivable that high Tyndall
effect at initial documentation correlated with subsequent
uveitis reactivation in the present study.
Previous retrospective results indicated that arthritis
and uveitis activity are commonly independent of each
other [40], and retrospective analysis did not find a signifi-
cant relationship between the time point of clinical remis-
sion for arthritis and uveitis [41]. Our previous study
showed that patients with high cJADAS-10 scores at
baseline had a higher risk of uveitis occurrence [18].
Accordingly, our data now show that moderate or high
JIA disease activity was a reliable predictor for subse-
quent uveitis reactivation.
Use of DMARDs is critical for achieving uveitis inactivity.
The common use of methotrexate in this study is in agree-
ment with previous publications [1, 42]. Methotrexate was
associated with a reduced risk of visual loss in recent
studies [10, 43], and also prevented uveitis onset when
treatment was commenced early after JIA onset [17, 18].
According to the data presented herein, however, metho-
trexate was not a predictor for attaining uveitis inactivity.
Recent studies with adalimumab found that uveitis in-
activity in methotrexate (combined with topical cortico-
steroids) non-responders is obtained in 53/4 of
patients, improving the subsequent disease course par-
ticularly when given early during the JIA course [6, 7, 18,
44]. In our study, under DMARDs (including adalimumab
use in up to 22.4% of included cases) uveitis inactivity
was documented in 81.8% and 80.0% of the JIAU pa-
tients at 1- and 2-year U-FU, respectively, which is in
agreement with previous publications. Indeed, our data
now point to adalimumab use as an important predictor
for achieving uveitis inactivity. Adalimumab has proven to
be effective for JIAU [7] and recently received approval for
this indication. Recent studies further suggested that
treatment with adalimumab reduced the uveitis incidence
in JIA patients [10, 18].
Uveitis-related complications and their predictors
In this study, the incidence of uveitis and second eye in-
volvement progressively increased during the first 2 years
after JIA onset in up to 2/3 of patients, supporting
previous observations [10, 12, 26, 30]. The numbers of
uveitis-related complications in JIA given herein during
the first 2-year course in ICON are in agreement with
recent publications providing longer follow-up [3, 10],
and the increasing complication rates during the long-
term course commonly reported [3, 4, 12, 28, 31].
Herein, late JIA onset and short duration between JIA
and uveitis onset were significant predictors for occur-
rence of uveitis-related eye complications. Accordingly,
higher complication rates were previously also found in
patients with late onset of arthritis, with uveitis presenting
before JIA onset or with a shorter interval between arthritis
and uveitis onset [3, 25, 26, 31, 45], probably related to
the longer disease period of insidious onset uveitis without
sufficient treatment.
Among the factors analysed herein, significant pre-
dictors for uveitis complications were high AC cell score,
and presence of complications and poor visual acuity at
first uveitis documentation. This is supported by a previ-
ous notion, as severity of uveitis at first uveitis documen-
tation was the most significant, independent risk factor for
subsequent development of complications [26]. In a pre-
vious study, increasing AC cell grade was associated with
increased rates of visual loss, while DMARD use was
associated with a reduced risk of visual loss [46].
Although high flare values (reflecting intraocular inflamma-
tion and also tissue damage) in JIAU patients were asso-
ciated with poor vision and a higher prevalence of uveitis
complications in previous studies [31, 39, 4749], no
TABLE 5 Uveitis-related eye complications at first uveitis documentation and at 1- and 2-year follow-up
Eye complication First uveitis documentation 1-year U-FU 2-year U-FU P-value
98 87a 75a
Any, n (%) 28 (29.8%) 23 (30.7%) 22 (32.8%) 0.845
Band-keratopathy, n (%) 2 (2.1%) 2 (2.3%) 1 (1.5%) 0.611
Synechiae, n (%) 21 (22.3%) 17 (22.7%) 16 (23.9%) 0.869
Cataract, n (%) 7 (7.5%) 7 (9.3%) 9 (13.4%) 0.377
Optic disc oedema, n (%) 1 (1.1%) 1 (1.3%) 0 (0.0%) 0.669
Macular oedema, n (%) 1 (1.1%) 0 (0.0%) 0 (0.0%) 0.484
Ocular hypertension, n (%) 0 (0.0%) 0 (0.0%) 4 (6.0%) 0.01
Glaucoma, n (%) 0 (0.0%) 1 (1.3%) 2 (3.0%) 0.228
Iris rubeosis, n (%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0.340
Vitreous haze, n (%) 2 (2.1%) 2 (2.7%) 1 (1.5%) 0.900
Any eye surgery, n (%) 0 (0.0%) 0 (0.0%) 1 (1.5%) 0.264
aOut of 98 patients, data from 87 patients were available at 1-year follow-up, and from 75 patients at 2-year follow-up. P-value
of less than 0.05 are indicated in bold. U-FU: uveitis follow-up.
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significant correlation was found for the Tyndall effect in
the present study.
In the present study, topical corticosteroid use was sig-
nificantly associated with the subsequent development of
uveitis-related eye complications, particularly cataract for-
mation, which is in accordance with previous reports [5].
Others showed that significantly higher amounts of oral
corticosteroids were used in patients with complications
[50], while this was not obvious in our study. While the rate
of uveitis-related complications was reduced under ada-
limumab treatment in previous publications [7, 18], our
present data disclose only a tendency for a reduced risk
for such complications, probably because most compli-
cations already existed at the initial study visit and
DMARD therapy, or because this analysis was limited to
2 years, and the preferential use of adalimumab in patients
with a severe JIAU course. Herein, no effect of conven-
tional synthetic DMARDs on the development of eye com-
plications could be demonstrated, supporting previous
findings [26], while DMARDs reduced the risk of hypotony
and other complications in a previous study [4].
Synechiae formation at initial presentation is often fol-
lowed by the development of vision-threatening compli-
cations [4, 26, 46], and their presence, AC flare 51+ and
TABLE 6 Association of initial clinical and laboratory parameters and treatment during follow-up with uveitis
complications
Parameter
Patients without uveitis
complications
Patients with uveitis
complications OR; 95% CI; P value
n= 61 n= 37
Female, n (%) 53 (80.3%) 26 (70.3%) 2.30; 0.60, 8.76; 0.224
Age at JIA onset, mean (S.D.), years 3.67 (2.92) 4.68 (3.55) 1.15; 1.01, 1.32; 0.039
Age at uveitis onset, mean (S.D.), years 4.62 (2.94) 4.92 (3.01) 1.10; 0.95, 1.27; 0.192
Uveitis onset >5 years, n (%) 19 (28.8%) 13 (35.1%) 1.99; 0.81, 4.91; 0.135
Interval between JIA and uveitis onset,
mean (S.D.), years
0.96 (1.05) 0.25 (1.56) 0.48; 0.23, 0.99; 0.046
JIA category, n (%)
Polyarthritis RF negative 15 (22.7%) 6 (17.1%) (Reference)
Oligoarthritis persistent 9 (13.6%) 3 (8.6%) 0.77; 0.08, 7.22; 0.822
Oligoarthritis extended 35 (53.0%) 19 (54.3%) 1.03; 0.21, 5.08; 0.968
Psoriatic arthritis 1 (1.5%) 2 (5.7%) 3.07; 0.07, 128.13; 0.554
Enthesitis-related arthritis 3 (4.6%) 3 (8.6%) 2.98; 0.17, 51.69; 0.452
Undifferentiated arthritis 3 (4.6%) 2 (5.7%) —
ANA positive, n (%) 54 (81.8%) 33 (89.2%) 1.86; 0.22, 16.00; 0.572
HLA-B27 positive, n (%) 5 (7.6%) 3 (8.1%) —
Laboratory markers
ESR, mean (S.D.) 23.40 (16.37) 24.27 (19.30) 1.01; 0.97, 1.05; 0.678
CRP, mean (S.D.) 7.07 (11.13) 4.04 (5.06) 0.95; 0.86, 1.04; 0.275
S100A12, mean (S.D.) 398.29 (608.21) 341.01 (452.86) 0.99; 0.99, 1.01; 0.387
Disease activity
cJADAS-10, mean (S.D.) 6.33 (4.29) 7.67 (4.17) 1.04; 0.90, 1.20; 0.627
Physician’s global, NRS, mean (S.D.) 2.46 (2.14) 2.81 (2.82) 0.95; 0.73, 1.23; 0.685
Number of active joints, mean (S.D.) 2.62 (2.21) 3.42 (2.05) 1.01; 0.69, 1.46; 0.891
Parent’s global, mean (S.D.) 1.25 (1.65) 1.44 (1.65) 1.20; 0.92, 1.57; 0.182
Pain, NRS, mean (S.D.) 2.19 (2.31) 2.19 (2.59) 1.10; 0.85, 1.41; 0.477
CHAQ, mean (S.D.) 0.51 (0.71) 0.65 (0.81) 1.54; 0.68, 3.53; 0.302
Uveitis activity, AC cell grade/
involved eye
0.87 (0.70) 1.23 (0.99) 2.24; 1.16, 4.31; 0.016
Tyndall/involved eye 1.55 (1.33) 1.96 (1.33) 1.16; 0.77, 1.75; 0.469
Visual acuity/involved eye, logMAR 0.11 (0.14) 0.40 (0.49) 9.95; 2.16, 45.83; 0.003
Anti-inflammatory treatment (time-varying)
NSAID 1.07; 0.36, 3.19
Any DMARDs 0.98; 0.60, 3.25
MTX 1.34; 0.42, 4.23
Etanercept ± MTX 0.94; 0.04, 24.68
Adalimumab ± MTX 0.64; 0.13, 1.09
CS, systemic 1.21; 0.22, 6.60
CS, topical, applications/day in
involved eyes
4.06; 1.63, 10.13
Clinical and laboratory parameters at first uveitis documentation and treatment during follow-up (time-varying) with uveitis
complications. P-value of less than 0.05 are indicated in bold. AC cell grade: anterior chamber cell grade; CHAQ: Childhood
Health Assessment Questionnaire; cJADAS: clinical juvenile arthritis disease activity score; CS: corticosteroids; NRS: numeric
rating scale; OR: odds ratio; PedsQL: Pediatric Quality of Life Inventory.
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hypotony were associated with vision loss or poor vision
during follow-up [4, 26, 43]. Herein, the presence of uve-
itis-related complications was not a significant predictor
for achieving uveitis inactivity under anti-inflammatory
treatment or subsequent reactivation.
Our study has some limitations. (i) ICON is an observa-
tional study and the analysis of treatment is a challenge.
The association between treatment and outcome is
biased by the individual treatment decision of the paedi-
atric rheumatologist or ophthalmologist. Patients on a
more severe disease course were more likely to be inten-
sively treated. Furthermore, treatment individually starts at
different time points depending on the disease course of
the patient and it is not possible to define a baseline for
comparisons. (ii) We did not collect data about the indica-
tion to start treatment. DMARD treatment may be initiated
to control the JIA disease activity or the uveitis activity.
(iii) The first uveitis documentation does not necessarily
reflect the assessment of uveitis activity at the uveitis
onset. Treatment may already have started before the
first documentation. However, during the recruitment
period, an estimated one-third of all new cases with JIA
in Germany were included in ICON and examined by
paediatric rheumatologists and ophthalmologists in a
standardized way, so that representative data on the uve-
itis outcome and its predictors could be obtained.
In summary, in addition to demographic risk factors, JIA
disease and uveitis activity scores and treatment with
adalimumab were significant predictors for the 2-year
course of JIAU patients in this inception cohort study.
Laboratory tests found to be significant biomarkers for
uveitis occurrence (e.g. ANA, ESR, S100), however, may
lose their respective predictive value for the disease
course under the influence of anti-inflammatory treatment
instituted early in the JIA course.
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